Targeted Therapy begins with LumiBRCATM & LumiTHERATM
Explore the viability of PARP inhibitor therapy for patients with breast or ovarian cancers with Lucence’s companion diagnostic tests: LumiBRCATM and LumiTHERATM.
Understanding BRCA1 & BRCA2
Also known as BReast CAncer1 & 2 genes, these genes are present in everyone and play an important role regulating cell growth in our bodies. But some people may have a mutated BRCA 1 and/or BRCA 2 genes and they will have a higher risk of developing breast or ovarian cancer.
The LumiBRCATM and LumiTHERATM cover a panel of genes associated with significantly increased risks of breast and ovarian cancer. Both tests are suitable for patients who want to explore targeted treatments
Frequently Asked Questions
What is the difference between LumiBRCATM and LumiTHERATM ?
LumiBRCATM tests for mutations involving the BRCA genes together with mutations arising from large genomic rearrangements.
LumiTHERATM is an expanded version of LumiBRCATM that includes the genes involved with the mismatch repair function.
How quickly can I expect the results for LumiBRCATM & LumiTHERATM ?
Results will be returned in 3 weeks.
If you are a practicing doctor in Singapore, you can order the tests with us online or call our sales hotline (+65 6592 5102). If you would like to find out more, we can schedule an appointment with you to explain our somatic and germline cancers tests in person.